Login to Your Account

Financings Roundup

Set for Late-Stage Transition, Array Pads Coffers with $66M

By Jennifer Boggs
Managing Editor

Monday, November 12, 2012
Only days after highlighting abstracts for its upcoming presentations at the American Society of Hematology (ASH) meeting in Atlanta and CEO Ron Squarer's assertion that his firm was "evolving into a late-stage development company" with five programs moving toward pivotal decisions in 2013, Array BioPharma Inc. is doubling its cash position with a $65.7 million public offering.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription